ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 9,080,000 shares, a growth of 17.2% from the July 15th total of 7,750,000 shares. Approximately 30.5% of the shares of the company are short sold. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is currently 7.1 days.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the transaction, the insider now owns 593,447 shares of the company’s stock, valued at approximately $4,688,231.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the sale, the insider now owns 593,447 shares of the company’s stock, valued at approximately $4,688,231.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Peter S. Garcia bought 12,000 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were bought at an average price of $8.53 per share, with a total value of $102,360.00. Following the completion of the transaction, the chief financial officer now owns 122,348 shares of the company’s stock, valued at $1,043,628.44. The disclosure for this purchase can be found here. Insiders sold 48,398 shares of company stock valued at $368,643 over the last three months. Company insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

A number of hedge funds have recently modified their holdings of ALXO. Algert Global LLC bought a new stake in shares of ALX Oncology in the 2nd quarter worth approximately $249,000. AQR Capital Management LLC boosted its holdings in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after acquiring an additional 6,080 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of ALX Oncology in the second quarter worth $1,203,000. Marshall Wace LLP increased its holdings in shares of ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after acquiring an additional 514,133 shares in the last quarter. Finally, Inspire Investing LLC raised its position in shares of ALX Oncology by 77.1% in the 2nd quarter. Inspire Investing LLC now owns 58,707 shares of the company’s stock worth $354,000 after purchasing an additional 25,551 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALXO has been the subject of several research analyst reports. UBS Group dropped their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a report on Tuesday, August 13th. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, ALX Oncology currently has an average rating of “Moderate Buy” and an average price target of $14.00.

ALX Oncology Trading Down 4.2 %

ALXO stock traded down $0.11 during trading on Friday, reaching $2.54. The company had a trading volume of 845,086 shares, compared to its average volume of 821,045. The business has a 50 day moving average of $5.72 and a 200 day moving average of $11.03. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21. The company has a market cap of $132.33 million, a P/E ratio of -0.68 and a beta of 1.06. ALX Oncology has a 52 week low of $2.42 and a 52 week high of $17.83.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. As a group, sell-side analysts forecast that ALX Oncology will post -2.89 earnings per share for the current fiscal year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.